Compare Mesoblast Limited (MESO) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Procter & Gamble Co — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Procter & Gamble Co trades at $145.19 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 157.6× Mesoblast Limited's market cap, and Procter & Gamble Co pays a 2.97% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PG | |
|---|---|---|
Market Cap | $2.16B | $340.39B |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $167.18 |
52-Week Low | $12.88 | $138.10 |
Enterprise Value | $2.17B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Procter & Gamble (PG) trades at $145.21, down 0.39% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and a strong net margin of 18.44%. Recent earnings have consistently beaten expectations, and a dividend of $1.09 per share is scheduled for payment in August 2026. Analyst consensus is bullish with a price target of $161.20, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.
PG offers stability with consistent earnings beats and a reliable dividend, but premium valuations and soft demand outlook pose near-term risks. Supply chain improvements and brand partnerships provide growth catalysts, while economic sensitivity and competitive pressures remain headwinds. The stock presents a balanced opportunity for income-focused investors seeking defensive exposure amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
